PRESS RELEASE: IVI Appoints Dr. Richard Chapman as Chief Science Officer

Alexandria, VA — January 26, 2021 — The Innovation and Value Initiative (IVI) — a nonprofit organization dedicated to advancing the science, practice, and use of value assessment in healthcare — today announced that Rick Chapman, PhD, will be its next Chief Science Officer. Chapman, who is currently Director of Health Economics at the Institute [...]

2021-03-23T18:38:16-04:00January 26th, 2021|News, Press|

Measuring Value: COVID-19 Forces a Reassessment

Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]

2020-12-29T17:02:53-05:00May 20th, 2020|Blog|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

2021-03-23T18:52:28-04:00December 10th, 2019|News, Press|

IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA

IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]

2019-11-13T13:07:31-05:00November 13th, 2019|News, Viewpoints|

IVI Comment Letter on ICER’s Proposed Methods for Curative Therapies

IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings by decision makers, specifically when short-term budget estimates may discourage investment in therapies with high long-term value, including careful consideration [...]

2019-09-16T12:50:24-04:00September 16th, 2019|News|

IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making

CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, "The neat 'answer' regarding the value of treatment [...]

2018-08-24T13:20:36-04:00August 17th, 2018|News, Viewpoints|

PRESS RELEASE: IVI Responds to ICER’s New Pilot Program

The Institute for Clinical Economic Review (ICER) recently launched a new pilot program that will allow more extensive evaluation of draft economic models used in ICER's reports. In response to ICER's new program, Mark Linthicum, Director of Scientific Communications for the Innovation and Value Initiative (IVI), commented: "The Innovation and Value Initiative (IVI) is working diligently [...]

2021-03-23T19:08:56-04:00April 3rd, 2018|News, Press|
Go to Top